Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Azacitidine 33venetoclax 10decitabine and cedazuridine drug combination 7Decitabine 7sabatolimab 3pevonedistat 3cedazuridine 3ON 01910 3spartalizumab 2glasdegib 2cc-486 2Panobinostat 2Cytarabine 2BI 6727 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1triciribine 1tipifarnib 1terameprocol 1tapotoclax 1tagraxofusp 1ruxolitinib 1orludodstat 1navitoclax 1lonafarnib 1lintuzumab 1lenzilumab 1guadecitabine 1exatecan 1bisantrene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Chronic × triciribine × Clear all
NCT00642031 2016-08-09

Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies

Prescient Therapeutics, Ltd.

Phase 1 Completed
20 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡